\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesOASC (Open & Agile Smart Cities & Communities) is a partner in the ACCEND project, a Europe-wide project building the foundations for a stronger, more connected deep tech scaleup scene.
If you're developing solutions for Smart Cities, Net Zero Cities or Regenerative Cites, you might be interested in this opportunity to accelerate your growth, access cross-border testbed and scale across Europe with the support of leading innovation partners.
ACCEND helps deep tech scaleups:
strengthen market readiness
access high-quality piloting environments across Europe
build connections with cities and investors
fast-track expansion into new European markets
With the deadline on april 15th you still have a chance to apply: fill out the application form here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
